Paradoxical Increase of Stroke in Patients with Defect of High Molecular Weight Multimers of the von Willebrand Factors following Transcatheter Aortic Valve Replacement

Abstract

Background Stroke is a major cause of disability after transcatheter aortic valve replacement (TAVR) and stroke prediction models and data are crucially needed. Following TAVR, high molecular weight (HMW) multimers defect of von Willebrand factor (VWF) as assessed by closure time of adenosine diphosphate (CT-ADP) value > 180 seconds is an independent predictor of bleeding events. This study sought to identify predictors of ischemic neurological events in patients who underwent TAVR and the specific impact of HMW multimers defect of VWF.

Methods Patients were prospectively enrolled between November 2012 and May 2018 at our institution. The CT-ADP, a point-of-care measure of hemostasis, was assessed the day before and 24 hours after the procedures. The rate of ischemic stroke and transient ischemic attack (TIA) was recorded up to 30 days after the procedures.

Results Of 565 TAVR patients, ischemic stroke/TIA was observed in 21 (3.7%) patients within 30 days. Ischemic stroke/TIA was associated with major/life-threatening bleeding complications (MLBCs) (9 [43%] vs. 88 [16%], p = 0.002) and postprocedure CT-ADP > 180 seconds (10 [48%] vs. 116 [21%], p = 0.01). By multivariate analysis, MLBCs (odds ratio [OR]: 3.58; 95% confidence interval [CI]: 1.45–8.84; p = 0.006) and postprocedure CT-ADP > 180 seconds (OR: 3.38; 95% CI: 1.38–8.25; p = 0.008) were evidenced as independent predictors of ischemic stroke/TIA.

Conclusion MLBCs and CT-ADP > 180 seconds were identified as predictors for ischemic stroke or TIA. The present study suggests that the defects of HMW multimers of the VWFs may contribute not only to bleeding events but also to thrombotic events.

Keywords

transcatheter aortic valve replacement - ischemic stroke - closure time of adenosine diphosphate - bleeding

• References

• 1 Smith CR, Leon MB, Mack MJ. , et al; PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011; 364 (23) 2187-2198
• 2 Thyregod HG, Steinbrüchel DA, Ihlemann N. , et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the all-comers notion randomized clinical trial. J Am Coll Cardiol 2015; 65 (20) 2184-2194
• 3 Popma JJ, Deeb GM, Yakubov SJ. , et al; Evolut Low Risk Trial Investigators. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 2019; 380 (18) 1706-1715
• 4 Wendler O, Schymik G, Treede H. , et al. Source 3 registry: design and 30-day results of the European Postapproval Registry of the latest generation of the Sapien 3 transcatheter heart valve. Circulation 2017; 135 (12) 1123-1132
• 5 Manoharan G, Van Mieghem NM, Windecker S. , et al. 1-year outcomes with the Evolut R self-expanding transcatheter aortic valve: from the international forward study. JACC Cardiovasc Interv 2018; 11 (22) 2326-2334
• 6 Durko AP, Reardon MJ, Kleiman NS. , et al. Neurological complications after transcatheter versus surgical aortic valve replacement in intermediate-risk patients. J Am Coll Cardiol 2018; 72 (18) 2109-2119
• 7 Kapadia SR, Huded CP, Kodali SK. , et al; PARTNER Trial Investigators. Stroke after surgical versus transfemoral transcatheter aortic valve replacement in the PARTNER trial. J Am Coll Cardiol 2018; 72 (20) 2415-2426
• 8 Kapadia S, Agarwal S, Miller DC. , et al. Insights into timing, risk factors, and outcomes of stroke and transient ischemic attack after transcatheter aortic valve replacement in the partner trial (placement of aortic transcatheter valves). Circ Cardiovasc Interv 2016; 9 (09) e002981
• 9 Kochar A, Li Z, Harrison JK. , et al. Stroke and cardiovascular outcomes in patients with carotid disease undergoing transcatheter aortic valve replacement. Circ Cardiovasc Interv 2018; 11 (06) e006322
• 10 Bosmans J, Bleiziffer S, Gerckens U. , et al; ADVANCE Study Investigators. The incidence and predictors of early- and mid-term clinically relevant neurological events after transcatheter aortic valve replacement in real-world patients. J Am Coll Cardiol 2015; 66 (03) 209-217
• 11 Kapadia SR, Kodali S, Makkar R. , et al; SENTINEL Trial Investigators. Protection against cerebral embolism during transcatheter aortic valve replacement. J Am Coll Cardiol 2017; 69 (04) 367-377
• 12 Van Mieghem NM, Schipper ME, Ladich E. , et al. Histopathology of embolic debris captured during transcatheter aortic valve replacement. Circulation 2013; 127 (22) 2194-2201
• 13 Freeman M, Barbanti M, Wood DA, Ye J, Webb JG. Cerebral events and protection during transcatheter aortic valve replacement. Catheter Cardiovasc Interv 2014; 84 (06) 885-896
• 14 Fanning JP, Walters DL, Platts DG, Eeles E, Bellapart J, Fraser JF. Characterization of neurological injury in transcatheter aortic valve implantation: how clear is the picture?. Circulation 2014; 129 (04) 504-515
• 15 Tchetche D, Farah B, Misuraca L. , et al. Cerebrovascular events post-transcatheter aortic valve replacement in a large cohort of patients: a FRANCE-2 registry substudy. JACC Cardiovasc Interv 2014; 7 (10) 1138-1145
• 16 Tchetche D, Van der Boon RM, Dumonteil N. , et al. Adverse impact of bleeding and transfusion on the outcome post-transcatheter aortic valve implantation: insights from the Pooled-RotterdAm-Milano-Toulouse In Collaboration Plus (PRAGMATIC Plus) initiative. Am Heart J 2012; 164 (03) 402-409
• 17 Kibler M, Marchandot B, Messas N. , et al. CT-ADP point-of-care assay predicts 30-day paravalvular aortic regurgitation and bleeding events following transcatheter aortic valve replacement. Thromb Haemost 2018; 118 (05) 893-905
• 18 Van Belle E, Rauch A, Vincent F. , et al. Von Willebrand factor multimers during transcatheter aortic-valve replacement. N Engl J Med 2016; 375 (04) 335-344
• 19 Kibler M, Marchandot B, Messas N. , et al. Primary hemostatic disorders and late major bleeding after transcatheter aortic valve replacement. J Am Coll Cardiol 2018; 72 (18) 2139-2148
• 20 Morel O, El Ghannudi S, Jesel L. , et al. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. J Am Coll Cardiol 2011; 57 (04) 399-408
• 21 Rodés-Cabau J, Dauerman HL, Cohen MG. , et al. Antithrombotic treatment in transcatheter aortic valve implantation: insights for cerebrovascular and bleeding events. J Am Coll Cardiol 2013; 62 (25) 2349-2359
• 22 Kleiman NS, Maini BJ, Reardon MJ. , et al; CoreValve Investigators. Neurological events following transcatheter aortic valve replacement and their predictors: a report from the CoreValve trials. Circ Cardiovasc Interv 2016; 9 (09) e003551
• 23 Bahrainwala ZS, Grega MA, Hogue CW. , et al. Intraoperative hemoglobin levels and transfusion independently predict stroke after cardiac operations. Ann Thorac Surg 2011; 91 (04) 1113-1118
• 24 Van Belle E, Rauch A, Vincentelli A. , et al. Von Willebrand factor as a biological sensor of blood flow to monitor percutaneous aortic valve interventions. Circ Res 2015; 116 (07) 1193-1201
• 25 Matsushita K, Marchandot B, Kibler M. , et al. P2Y12 inhibition by clopidogrel increases periprocedural bleeds in patients undergoing transcatheter aortic valve replacement. J Am Coll Cardiol 2019; 74 (21) 2707-2708
• 26 Rodés-Cabau J, Masson JB, Welsh RC. , et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the arte (aspirin versus aspirin + clopidogrel following transcatheter aortic valve implantation) randomized clinical trial. JACC Cardiovasc Interv 2017; 10 (13) 1357-1365
• 27 Jimenez C, Ohana M, Marchandot B. , et al. Impact of antithrombotic regimen and platelet inhibition extent on leaflet thrombosis detected by cardiac MDCT after transcatheter aortic valve replacement. J Clin Med 2019; 8 (04) E506
• 28 Chakravarty T, Søndergaard L, Friedman J. , et al; RESOLVE; SAVORY Investigators. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet 2017; 389 (10087): 2383-2392
• 29 Dangas GD, Tijssen JGP, Wöhrle J. , et al; GALILEO Investigators. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med 2020; 382 (02) 120-129